Home >> Tag Archives: Bristol-Myers Squibb—

Tag Archives: Bristol-Myers Squibb—

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Sam Caughron, MD, President & Managing Partner, Director of Molecular Lab, MAWD Pathology Group, discusses discusses Pathologists play a crucial role in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on November 29, 2018.

Read More »

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Tabetha Sundin, PhD, HCLD, MB, discusses the crucial role pathologists play in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on October 3, 2018.

Read More »

Yervoy OK’d for MSI-H/dMMR mCRC patients

July 13, 2018—The FDA granted accelerated approval to ipilimumab (Yervoy, Bristol-Myers Squibb) for use in combination with nivolumab (Opdivo, BMS) for the treatment of patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read More »

Opdivo OK’d for adjuvant treatment of melanoma

Jan. 4, 2018—Bristol-Myers Squibb announced the FDA has approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce the risk of recurrence following surgical removal of the tumor and lymph nodes that contain cancer. ...

Read More »
X